Trial Profile
A biomarker study to study latent hypothyreosis as a clinical biomarker for therapy response under abiraterone acetate therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Dec 2015
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics
- 10 Dec 2015 New trial record